Normally, this mechanism promotes antigen presentation in target tumor cells and creates an environment conducive to antitumor effects, but in tumor cells with genetic mutations that induce acquired resistance, the signaling system from interferon-gamma becomes completely dysfunctional and the tumor cells themselves are unable to present antigen. Here, IFNG is linked to neoplasm.